Osteoporosis – a Silent Epidemic of XXI Century: Secondary Forms
Abstract
The objective of the study was to determine the main causes of osteoporosis in chronic kidney disease, chronic obstructive pulmonary disease, pulmonary sarcoidosis and understand how the disease develops in these conditions.
Materials and Methods. To study the mechanisms of developing secondary osteoporosis, a literature review was conducted.
Results. Secondary forms of osteoporosis account for approximately 15-20% of reported cases and result mainly from concomitant diseases or from using drugs that have a negative effect on bone tissue. Despite its inert and stable appearance, bone tissue is a metabolically active, continuously renewing system. Throughout life, it continuously undergoes remodeling cycles involving the two main processes: the first one is called bone resorption and involves the breakdown of old bone followed by the destruction and removal of both the mineral substance and the organic matrix from resorption sites; the second one is called new bone formation and involves bone matrix synthesis and its subsequent mineralization. The imbalance between these two processes, the predominance of bone resorption over bone formation, is the key link in the pathogenesis of osteoporosis. Such an imbalance reflects the impairment of the major mechanisms of systemic hormonal and local (cytokine) regulation of cellular activity and occurs in secondary osteoporosis.
Conclusions. To date, at the stage of providing medical care to patients with chronic bronchopulmonary diseases and chronic kidney disease, inadequate attention is paid to timely diagnosis and treatment of concomitant osteoporosis. The latter often develops as a secondary condition due to systemic inflammation, severe hypoxia, low physical activity, taking inhaled and systemic glucocorticoids. Its signs are not clinically apparent; hence, it is referred to as the ‘silent epidemic. Since osteoporosis has no pathognomonic symptoms and its clinical presentation is rather vague, in patients with chronic bronchopulmonary diseases and chronic kidney disease, its early diagnosis by determining mineral bone density is recommended to prevent the development of severe complications, including low-energy fractures.
References
Baranova IA. Diagnostika i lecheniye gliukokortikoidnogo osteoporoza. Farmateka. 2014; 7:12-8.
Baranova IA. Osteoporoz v praktike pulmonologa. Farmateka. 2013; 5:14-20.
Golovach IYu. Innovatsyonnyie podkhody k lecheniiu vertebralnykh perelomov u patsyientov s osteoporozom: ingibitor RANKL denosumab. Zdorovia Ukrainy. 2013; Tematychnyi nomer Berezen:25-6.
Mytrokhina O, Lysunets T. Zoledronic acid in the therapy of steroid-induced osteoporosis in patients with inflammatory joints disease. Bol. Sustavy. Pozvonochnik. 2016;1 (21):79-80.
Kochysh AYu, Ivanov SN, Sannikova YeV. Priverzhennost diagnostike osteoporoza u patsyientov s maloenergeticheskimi perelomami kostei. Farmateka. 2015; 5:78-82.
Rozhynskaia LYa. Osteoporoz: aktualnaia problema. Farmateka. 2012; 1:54-62.
Povorozniuk VV, Balatska NI. Defitsyt vitamin D u naselennia Ukrainy ta factory ryzyku yoho rozvytku. Bol. Sustavy. Pozvonochnik. 2012;4 (08):32-7.
Fomina LA, Ziabreva IA. Epidemiologicheskiie aspekty osteoporoza I osteopenia. Verkhnevolzhskii meditsinskii zhurnal. 2014;12(4):21-5.
Kochysh AYu, Ivanov SN. Sravnitelnoie issledovaniie effektivnosti otechestvennogo generika I originalnogo preparata zolendronovoi kisloty u patsyentov s maloenergeticheskimi perelomami tel pozvonkov I postmenopauzalnym osteoporozom. Farmateka. 2014;s5-14:24-9.
Biriukova YeV. Vozmozhnosti primeneniia zolendronata v lechenii osteoporoza. Farmateka. 2014;s5-14:18-23.
Biriukova YeV. Vse li my znaiem o vozmozhnostiah lecheniia steroidnogo osteoporoza? Farmateka. 2013;s4-15:22-7.
Martyniuk LP, Martyniuk LP, Ruzhytska OO. Osoblyvosti mineralnoho obminu ta funktsii parashchytopodibnykh zaloz pry khronichnii khvorobi nyrok. PJS. 2012;2(6):72-9. Available at: https://doi.org/10.22141/2224-1507.2.06.2012.82245
Jager KJ, Kovesdy C, Langham R et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34:1803-5. Available at: https://doi.org/10.1093/ndt/gfz174
KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-¬Mineral and Bone Disorder (CKD-¬MBD). Kidney Int. Suppl. 2017;7:1-59. Available at: https://doi.org/10.1016/j.kisu.2017.04.001
Maslii KO, Cherenko SM. Chastota vtorynnoho hiperparatyreozu na tli defitsytu vitaminu D sered patsiientiv endokrynolohichnoho profiliu. Klinichna endokrynolohiia ta endokrynna khirurhiia. 2018;3(63):58-63.
Conigrave AD. The Calcium-Sensing Receptor and the Parathyroid: Past, Present, Future. Front Physiol. 2016;7:563. Available at: https://doi.org/10.3389/fphys.2016.00563
Egshatian L, Mokrysheva N, Rozhynskaia L. Vtorichnyi i tretichnyi giperparatireoz pri khronicheskoi bolezni pochek. Osteoporoz i osteopatii. 2017;20(2):63-8.
Tkachenko RP, Kuryk OH, Denysenko AI, Hubar OS. Vtorynnyi ta tretynnyi hiperparatyreoz: shliakhy vyrishennia problemy. Visnyk VDNZU "Ukrainska medychna stomatolohichna akademiia". 2016;Т.16,vyp.4(56), ch.1:206-15.
Mokrysheva N, Yeromkina A, Mirnaia S, Kovalova Ye. Trudnosti differentsyalnoi diagnostiki mezhdu pervichnoi I vtorychnoi formami giperparatireoza. Ozhyreniie i metabolism. 2017;14(3):48-53. Available at: https://doi.org/10.14341/omet2017348-53
Desiateryk VI, Mihno SP, Zalozna OV, Lytvyn AM. Khirurhichni problem vtorynnoho i tretynnoho hiperparatyreozu v dializnykh patsiientiv iz khronichnoiu nyrkovoiu nedostatnistiu. Shpytalna khirurhiia. Zhurnal imeni L.Ya.Kovalchuka. 2020;1:62-4.
Hou YC, Lu CL, Lu KC. Mineral bone disorders in chronic kidney disease. Nephrology (Carlton). 2018; 23, Suppl 4:88-94. Available at: https://doi.org/10.1111/nep.13457
Hsu CY, Chen LR, Chen KH. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review. Int J Mol Sci. 2020; 21(18):6846. Available at: https://doi.org/10.3390/ijms21186846
Yi-Chou Hou, Chien-Lin Lu, Kuo-Cheng Lu. Mineral bone disorders in chronic kidney disease. Nephrology. 2018; 23, Suppl.4:88-94. Available at: https://doi.org/10.1111/nep.13457
Wakasugi M, Kazama JJ, Wada A, Hamano T, Masakane I, Narita I. Hip fracture trends in Japanese dialysis patients, 2008-2013. Am. J. Kidney Dis. 2018; 71:173-81. Available at: https://doi.org/10.1053/j.ajkd.2017.07.017
Malmgren L, McGuigan F, Christensson A, Akesson KE. Reduced kidney function is associated with BMD, bone loss and markers of mineral homeostasis in older women: A 10-year longitudinal study. Osteoporosis. 2017; 28:3463-73. Available at: https://doi.org/10.1007/s00198-017-4221-y
Fukagawa M, Komaba H. Chronic kidney disease-mineral and bone disorder in Asia. Kidney Dis. 2017; 3:1-7. Available at: https://doi.org/10.1159/000470909
Yashyna LO, Humeniuk MI, Ignatieva VI, Humeniuk HL. Osoblyvosti etiolohii ta patogenezu osteoporozu u khvorykh na khronichne obstruktyvne zakhvoriuvannia lehen. Astma ta alergiia. 2013; 2:35-41.
Humeniuk MI, Ignatieva VI, Humeniuk HL, Lynnyk MI. Aktualnist diagnostyky osteoporozu u khvorykh na bronkhoobstruktyvni zakhvoriuvannia lehen, yaki otrymuiut hliukokortykosteroidy. Ukpainskyi khimioterapevtychnyi zhurnal. 2013;1(28):42-46.
Yashyna LO, Humeniuk MI, Ignatieva VI, Lynnyk MI. Porivniannia informatyvnosti doslidzhennia shchilnosti kistok verkhnioi shchelepy ta standartnykh pokaznykiv osteoporozu u khvorykh na khronichne obstruktyvne zakhvoriuvannia lehen. Astma ta alergiia. 2020; 2:42-49.
Chaplynska NV, Rudnyk VT, Symchych KS. Khronichne obstruktyvne zakhvoriuvannia lehen: pozalehenevi proiavy. Bukovynskyi medychnyi visnyk. 2017; Vol 21; 4(84). Available at:
https://doi.org/10.24061/2413-0737.XXI.4.84.2017.136
Daisuke Inoue, Reiko Watanabe, Ryo Okazaki. COPD and osteoporosis: links, risks, and treatment challenges. Int J. Chron Obstruct Pulmon Dis. 2016; 11:637-48. Available at: https://doi.org/10.2147/COPD.S79638
American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis and Rheumatology. 2017;8,Vol 69: 1521-37. Available at: https://doi.org/10.1002/art.40137
Merenkova EA. Chastota retsidivov y lits, klinicheski izlechonnykh ot sarkoidoza legkikh. Ukrainskyi pulmonolohichnyi zhurnal. 2018;101(3):28-33. Available at: https://doi.org/10.31215/2306-4927-2018-101-3-28-33
Merenkova EA, Vlasova NA. Retsidivy pri sarkoidoze legkikh. Ukrainskyi pulmonolohichnyi zhurnal. 2020; 2:67-70. Available at: https://doi.org/10.31215/2306-4927-2020-108-2-67-70
Havrysiuk VK, Merenkova EA, Vlasova NA, Bychenko OV. Klinicheskaia model fenotipa patsyienta s retcidiviruiushchim sarkoidozom legkikh. Ukrainskyi pulmonolohichnyi zhurnal. 2020; 3:53-57. Available at: https://doi.org/10.31215/2306-4927-2020-109-3-53-57
Copyright (c) 2023 Roman Yatsyshyn, Nataliia Cherniuk, Oksana Drohomeretska, Vitalii Kaminskyi, Petro Gerych, Ivan Stoika, Oleksandra Hotsaniuk, Vira Vyshyvanyuk
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
